Document:

EX-10.43

 Exhibit 10.43 

SENIOR VICE PRESIDENT SEVERANCE AGREEMENT 

THIS AGREEMENT made as of the              day of
            , 2013, by and between Hologic, Inc., a Delaware corporation, and
                     (the “Executive”). 

WHEREAS, the Board of Directors (the “Board”) of the Company (as hereinafter defined) recognizes that the possibility of a
termination without Cause (as hereinafter defined), can create significant distractions for its key management personnel because of the uncertainties inherent in such situations; 

WHEREAS, the Board has determined that it is essential and in the best interest of the Company and its stockholders to retain the
services of the Executive, in general and to ensure his or her continued and full attention, dedication and efforts in such event without undue concern for his or her personal financial and employment security; 

WHEREAS, the Executive may have been previously entitled to severance benefits pursuant to a separation agreement, in which case that
agreement shall be superseded and replaced by this Agreement; and 
 WHEREAS, in order to induce the Executive to remain in the
employ of the Company, the Company desires to enter into this Agreement with the Executive to provide the Executive with severance benefits, in the event his or her employment is terminated in certain circumstances, in accordance with the terms and
conditions set forth herein. 
 NOW, THEREFORE, in consideration of the respective agreements of the parties contained herein, it is
agreed as follows: 
 l. TERM OF AGREEMENT. This Agreement shall commence as of the date hereof, and shall continue in effect until Executive’s
employment with the Company terminates. 
 2. DEFINITIONS. 

2.1 ACCRUED COMPENSATION. For purposes of this Agreement, “Accrued Compensation” shall mean an amount which shall include all amounts earned
or accrued through the Termination Date (as hereinafter defined) but not paid as of the Termination Date, including (i) Base Salary, (ii) reimbursement for reasonable and necessary business expenses incurred by the Executive on behalf of
the Company, pursuant to the Company’s expense reimbursement policy in effect at such time, during the period ending on the Termination Date, and (iii) vacation pay. 

2.2 BASE SALARY. For purposes of this Agreement, “Base Salary” shall mean the greater of the Executive’s annual base salary (a) at
the rate in effect on the Termination Date or (b) at the highest rate in effect at any time during the ninety (90) day period immediately prior to the Termination Date, and shall include all amounts of his or her Base Salary that are
deferred at the election of the Executive under the qualified and non-qualified employee benefit plans of the Company or any other agreement or arrangement. For avoidance of doubt, Base Salary shall not include any bonus or portion thereof deferred
under the Company’s Bonus Deferral Program. 
 2.3 BONUS AMOUNT. For purposes of this Agreement, “Bonus Amount” shall mean the average
of the annual bonuses paid or that has been earned and accrued but not paid, in each case under the Company’s Short Term Incentive Plan, during the three full fiscal years ended prior to the Date of Termination. For avoidance of doubt, any
bonus electively deferred by the Executive pursuant to a qualified or non-qualified plan shall be included in the Bonus Amount. 

 2.4 CAUSE. The Company may terminate the Executive’s employment during the Term of this Agreement for
“Cause”. For purposes of this Agreement, “Cause” means (i) disloyalty, gross negligence, willfulness conduct or breach of fiduciary duty to the Company which results in substantial direct or indirect loss, damage or injury
to the Company; (ii) Executive’s material violation of the Company’s Code of Conduct and other Company Codes of Conduct or other policies or procedures that are applicable to the Executive; (iii) the commission, indictment, plea
of nolo contendere or conviction of Executive of a felony; (iv) the breach of the Executive’s confidentiality non-competition, non-solicitation covenants set forth in a separate written agreement between the Company and the
Executive, or (v) a violation of federal or states securities law or regulations. 
 2.5 COMPANY. For purposes of this Agreement,
“Company” shall mean Hologic, Inc. and shall include its successors and assigns. 
 2.6 DISABILITY. For purposes of this Agreement,
“Disability” shall mean a physical or mental infirmity which impairs the Executive’s ability to substantially perform his or her duties with the Company for a period of ninety (90) consecutive days, and the Executive has not
returned to his or her full time employment prior to the Termination Date. 
 2.7 PRO RATA BONUS. For purposes of this Agreement, “Pro Rata
Bonus” shall mean an amount equal to the Bonus Amount multiplied by a fraction the numerator of which is the number of months worked in the fiscal year through the Termination Date and the denominator of which is 12. Any partial months shall be
rounded to the nearest whole number using normal mathematical convention. 
 2.8 TERMINATION DATE. For purposes of this Agreement, “Termination
Date” shall mean in the case of the Executive’s death, his or her date of death, and in all other cases, the date specified in the Notice of Termination (as defined herein); provided, however, that if the Executive’s employment is
terminated by the Company for Cause or due to Disability, the date specified in the Notice of Termination shall be at least 30 days from the date the Notice of Termination is delivered to the Executive, provided that in the case of Disability the
Executive shall not have returned to the full-time performance of his or her duties during such period. 
 3. TERMINATION OF EMPLOYMENT. 

3.1 TERMINATION BENEFITS. If, during the term of this Agreement, the Executive’s employment with the Company is terminated, then the Executive
shall be entitled to the following compensation and benefits: 
 a. If the Executive’s employment with the Company is terminated
(1) by the Company for Cause or Disability, (2) by reason of the Executive’s death, or (3) by the Executive, the Company shall pay to the Executive the Accrued Compensation only. 

b. If the Executive’s employment with the Company shall be terminated by Company without Cause, then the Executive shall be entitled to
each and all of the following: 
  

	 	i.	The Company shall pay the Executive all Accrued Compensation; 

  

	 	ii.	The Company shall pay the Executive a Pro Rata Bonus; and 

  

	 	iii.	The Company shall continue to pay the Executive his or her or her Base Salary for the fifteen (15) months in accordance with its normal payroll practices and subject to applicable tax withholding.

  
 2 

 c. The Amounts provided for in Sections 3(a) and 3(b)(i) shall be paid in a single lump sum cash
payment within five (5) business days after the Executive’s Termination Date (or earlier, if required by applicable law). 
 3.2 MITIGATION.
The Executive shall not be required to mitigate the amount of any payment provided for in this Agreement by seeking other employment or otherwise and no such payment shall be offset or reduced by the amount of any compensation or benefits provided
to the Executive in any subsequent employment. 
 3.3 OTHER SEVERANCE BENEFITS. The severance pay and benefits provided for in this Section 3
shall be in lieu of any other severance or termination pay to which the Executive may be entitled under any Company severance or termination plan, program, practice or arrangement. The Executive’s entitlement to any other compensation or
benefits shall be determined in accordance with the Company’s employee benefit plans and other applicable programs, policies and practices then in effect. 

4. NOTICE OF TERMINATION. For purposes of this Agreement, “Notice of Termination” shall mean a written notice from the Company of termination
of the Executive’s employment which indicate the specific termination provision in this Agreement relied upon, if any, the effective date of termination, and which sets forth in reasonable detail the facts and circumstances claimed to provide a
basis for termination of the Executive’s employment under the provision so indicated. For purposes of this Agreement, no-such purported termination shall be effective without such Notice of Termination. 

5. EXCISE TAX PAYMENTS. 
 a.
Notwithstanding anything contained in this Agreement to the contrary, to the extent that the payments and benefits provided under this Agreement and benefits provided to, or for the benefit of, the Executive under any other Company plan or agreement
(such payments or benefits are collectively referred to as the “Payments”) would be subject to the excise tax (the “Excise Tax”) imposed under Section 4999 of the Internal Revenue Code of 1986, as amended (the
“Code”), the Payments shall be reduced (but not below zero) if and to the extent necessary so that no Payment to be made or benefit to be provided to the Executive shall be subject to the Excise Tax (such reduced amount is hereinafter
referred to as the “Limited Payment Amount”). Unless the Executive shall have given prior written notice specifying a different order to the Company to effectuate the Limited Payment Amount, the Company shall reduce or eliminate the
Payments, by first reducing or eliminating those payments or benefits which are not payable in cash and then by reducing or eliminating cash payments, in each case in reverse order beginning with payments or benefits which are to be paid the
farthest in time from the “Determination” (as hereinafter defined). Any notice given by the Executive pursuant to the preceding sentence shall take precedence over the provisions of any other plan, arrangement or agreement governing the
Executive’s rights and entitlements to any benefits or compensation. 
 b. An initial determination as to whether the Payments shall be
reduced to the Limited Payment Amount pursuant to the Plan and the amount of such Limited Payment Amount shall be made by an accounting firm at the Company’s expense selected by the Company which is designated as one of the six largest
accounting firms in the United States (the “Accounting Firm”). The Accounting Firm shall provide its determination (the “Determination”), together with detailed supporting calculations and documentation, to the Company and the
Executive within five (5) days of the Termination Date, if applicable, or such other time as requested by the Company or by the Executive (provided the Executive reasonably believes that any of the Payments may be subject to the Excise Tax),
and if the Accounting Firm determines that no Excise Tax is payable by the Executive with respect to a Payment or Payments, it shall furnish the Executive with an opinion, at the Company’s expense, reasonably acceptable to the Executive that no
Excise Tax will be imposed with respect to any such Payment or Payments. Within ten (10) days of the delivery of the Determination to the Executive, the Executive shall have the right to dispute the Determination (the “Dispute”). If
there is no Dispute, the Determination shall be binding, final and conclusive upon the Company and the Executive subject to the application of Section 5(c) below. 

  
 3 

 c. As a result of the uncertainty in the application of Sections 4999 and 280G of the Code, it is
possible that the Payments to be made to, or provided for the benefit of, the Executive either have been made or have not been made by the Company which, in either case, will be inconsistent with the limitations provided in Section 5(a)
(hereinafter referred to as an “Excess Payment” or “Underpayment”, respectively). If it is established pursuant to a final determination of a court, or an Internal Revenue Service (the “IRS”) proceeding which has been
finally and conclusively resolved, that an Excess Payment has been made, such Excess Payment shall be deemed for all purposes to be a loan to the Executive made on the date the Executive received the Excess Payment and the Executive shall repay the
Excess Payment to the Company, on demand (but not less than thirty (30) days after written notice is received by the Executive), together with interest on the Excess Payment at the “Applicable Federal Rate” (as defined in
Section 1274(d) of the Code) from the date of the Executive’s receipt of such Excess Payment until the date of such repayment. In the event that it is determined by (i) the Accounting Firm, the Company (which shall include the
position taken by the Company, or together with its consolidated group, on its federal income tax return) or the IRS, (ii) pursuant to a determination by a court, or (iii) upon the resolution to the Executive’s satisfaction of the
Dispute, that an underpayment has occurred, the Company shall pay an amount equal to the Underpayment to the Executive within thirty (30) days of such determination or resolution, together with interest on such amount at the Applicable Federal
Rate from the date such amount would have been paid to the Executive until the date of payment. 
 d. Notwithstanding anything contained in
this Agreement to the contrary, in the event that, according to the Determination, an Excise Tax will be imposed on any Payment or Payments, the Company shall pay to the applicable government taxing authorities, as Excise Tax withholding, the amount
of the Excise Tax that the Company has actually withheld from the Payment or Payments. 
 6. SUCCESSORS. This Agreement shall be binding upon and
shall inure to the benefit of the Company and its permitted successors and assigns. In the event of a merger, sale of substantially all the assets of the Company, or other sale, divestiture, spin-out or other transfer or disposition by the Company
of any assets or business of the Company (a “Disposition”), pursuant to which the Executive becomes employed by the successor to such business or assets and such successor agrees to assume the Company’s obligations under this
Agreement, then such successor shall become a permitted successor and assign under this Agreement and the Company shall be relieved of all further obligations under this Agreement. In the event of a Disposition, pursuant to which the Executive is
offered employment by the successor to such assets or business with a Base Salary no less than his Base Salary with Company and such successor offers to assume the Company’s obligations under this Agreement, and the Executive does not accept
such employment, then this Agreement shall terminate immediately and neither the Company nor any such successor shall have any obligations hereunder. Neither this Agreement nor any right or interest hereunder shall be assignable or transferable by
the Executive, his or her beneficiaries or legal representatives, except by will or by the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal representative. 

7. ARBITRATION. Any dispute, controversy or claim arising out of or relating to this Agreement, or the breach, termination or invalidity hereof,
(collectively, a “Claim”) shall be settled by arbitration pursuant to the rules of the American Arbitration Association. Any such arbitration shall be conducted by one arbitrator, with experience in the matters covered by this Agreement,
mutually acceptable to the parties. If the parties are unable to agree on the arbitrator within thirty (30) days of one party giving the other party written notice of intent to arbitrate a Claim, the American Arbitration Association shall
appoint an arbitrator with such qualifications to conduct such arbitration. The decision of the arbitrator in any such arbitration shall be conclusive and binding on the parties. Any such arbitration shall be conducted in Boston, Massachusetts,
unless the Executive consents to a different location. 
 8. NOTICE. For the purposes of this Agreement, notices and all other communications provided
for in the Agreement (including the Notice of Termination) shall be in writing and shall be (i) delivered by hand, (ii) transmitted by facsimile or electronic mail with receipt confirmed, (iii) delivered by overnight courier service
with confirmed receipt or (iv) mailed by first class U.S. mail postage pre-paid and registered or certified, return receipt requested and addressed to the respective addresses last given by each party to the other, provided that all notices to

  
 4 

 
the Company shall be directed to the attention of the Board with a copy to the General Counsel of the Company. All notices and communications shall be deemed to have been received on the date of
delivery thereof or on the third business day after the mailing thereof, except that notice of change of address shall be effective only upon receipt. 
 9.
NON-EXCLUSIVITY OF RIGHTS. Nothing in this Agreement shall prevent or limit the Executive’s continuing or future participation in any benefit, bonus, incentive or other plan or program provided by the Company (except for any severance or
termination policies, plans, programs or practices) and for which the Executive may qualify, nor shall anything herein limit or reduce such rights as the Executive may have under any other agreements with the Company (except for any severance or
termination agreement). Amounts which are vested benefits or which the Executive is otherwise entitled to receive under any plan or program of the Company shall be payable in accordance with such plan or program, except as explicitly modified by
this Agreement. 
 10. 409A COMPLIANCE. Notwithstanding any other provision herein to the contrary, the Company shall make the payments required
hereunder in compliance with the requirements of Section 409A of the Code and any interpretative guidance issued thereunder. The Company may, in its sole and absolute discretion, delay payments hereunder or make such other modifications with
respect to the timing of payments as it deems necessary to comply with Section 409A of the Code. 
 11. RELEASE. The Executive agrees that, with
the exception of the Accrued Compensation due to him in accordance with the terms hereunder, that the payment of any severance under Sections 3(b)(ii) and (iii) is subject to and conditioned upon the execution and delivery by the Executive to
the Company of a Settlement and Release Agreement (the “Release Agreement”) in favor of the Company, its affiliates and their respective officers, directors, employees and agents in respect to the Executive’s employment with the
Company and the termination thereof in a form suitable to the Company and the expiration of any revocation period provided for under the Release Agreement. Notwithstanding anything herein to the contrary, in the event that the consideration and
revocation period provided for in the Release Agreement begins in one calendar year and could expire in the second calendar year, then the payment provided in Section 3(b)(ii) as well as commencement of the payment in Section 3(b)(iii)
shall be made or, if applicable, commence in the second calendar year. 
 12. NO EMPLOYMENT RIGHT. This Agreement does not constitute, and shall not
be construed to provide, any assurance of continuing employment. Executive’s employment with the Company and of its Successors or Assigns is “at will” and, subject to the terms and conditions of this Agreement, may be terminated by
Executive or the Company at any time. 
 13. OTHER CHANGE IN CONTROL AGREEMENT. Notwithstanding anything herein to the contrary, if the Executive is a
party to a Change of Control Agreement with the Company and such Agreement results in the payment of benefits to the Executive as the result of a change in control then the Executive shall receive no compensation hereunder. 

14. MISCELLANEOUS. No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in
writing, specifying such modification, waiver or discharge, and signed by the Executive and the Company. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this
Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. 

15. GOVERNING LAW. This Agreement shall be governed by and construed and enforced in accordance with the laws of the Commonwealth of Massachusetts
without giving effect to the conflict of laws principles thereof. Any action brought by any party to this Agreement to enforce any decision of an arbitrator made as contemplated in Section 7 above shall be brought and maintained in a court of
competent jurisdiction in the Commonwealth of Massachusetts. 

  
 5 

 16. SEVERABILITY. The provisions of this Agreement shall be deemed severable, and the invalidity or
unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. 
 17. ENTIRE AGREEMENT. This
Agreement constitutes the entire agreement between the parties hereto and supersedes all prior severance agreements, if any, understandings and arrangements, oral or written, between the parties hereto with respect to the subject matter hereof,
provided, however, that any Change of Control Agreement, option agreement, Assignment of Intellectual Property and Non-Competition Agreement shall remain in full force and effect. 

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer and the Executive has executed this Agreement as
of the day and year first above written. 
  

			
	Hologic, Inc.
		
	By:	 	 
	Date:	 	  

  

			
	Executive
	
	  

<Name>

	Date:	 	  

  
 6 

 Schedule to Senior Vice President Severance Agreement 

The following is a list of our officers who are party to the Company’s Senior Vice President Severance Agreement, the form of which is
filed herewith: 
 Arthur Friedman 
 Stephen Furlong 

David Harding 
 Rohan Hastie, Ph.D. 

Carter Houghton 
 Zhenxue Jing 

Robert Lavallee 
 Roger Mills 

John Pekarsky 
 David Rudzinsky 

Jay Stein 
 Monte Tucker 

Thomas Umbel 

  
 7EX-10.57

 Exhibit 10.57 

FIRST AMENDMENT TO 

Restated Agreement, dated July 24, 2009 

between 
 Gen-Probe
Incorporated 
 and 

Novartis Vaccines and Diagnostics, Inc. 

This first amendment, dated November 8, 2013, (the “First Amendment”) to the Restated Agreement, dated as of July 24, 2009, (the
“Agreement”) is made by and between Hologic Gen-Probe Incorporated, formerly known as Gen-Probe Incorporated (“Gen-Probe”), a Delaware corporation with a place of business at 10210 Genetic Center
Drive, San Diego, CA 92121-4362, and Novartis Vaccines and Diagnostics, Inc. (“Novartis”), a Delaware corporation with a place of business at 4560 Horton Street, Emeryville, CA 94608. Capitalized terms not defined in this
First Amendment shall have the same meanings given them in the Agreement. 
 RECITALS 

 

	 	A.	WHEREAS, as of the date Gen-Probe and Novartis entered into the Agreement, Novartis was a party to an agreement between the U.S. National Institutes of Health (“NIH”) and Novartis (the
“NIH-Novartis Agreement”), and Institut Pasteur, NIH and Novartis were in discussions regarding the joinder of Institut Pasteur to such NIH-Novartis Agreement or a similar arrangement. The terms of the NIH—Novartis
Agreement would have required certain payments to NIH for a license of its HIV-1 intellectual property. 

  

	 	B.	WHEREAS, the Agreement sets forth the payment obligations of Gen-Probe to Novartis with respect to the with respect to the HIV-1 intellectual property rights owned by NIH and Institut Pasteur. 

 

	 	C.	WHEREAS, the NIH-Novartis Agreement is no longer in effect. 

  

	 	D.	WHEREAS, Novartis currently is party to that certain three-way patent interference dispute between Novartis Patent 6,531,276 and NIH App. Ser. No. 06/693,866 filed January 23, 1985 and Institut Pasteur
App. Ser. No. 07/999,410 filed December 31, 1992, on appeal in the District Court for the District of Columbia, Civ. Action No. 07-cv-0034 as such dispute may evolve and be supplemented or modified from time to time (the “Current
NIH-Pasteur Dispute”). 

  

	 	E.	WHEREAS, Novartis and Gen-Probe now desire to revise the Agreement to eliminate Gen-Probe’s obligation to share in any payment obligations of Novartis arising from the settlement or other resolution of the
Current NIH–Pasteur Dispute. 

 NOW, THEREFORE, in consideration of the mutual representations, warranties and
covenants set forth in the Agreement and in this First Amendment and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Gen-Probe and Novartis agree as follows: 

AGREEMENT 
 1. Section 6.2 of the
Agreement is hereby deleted in its entirety. 
 2. Section 8.6 of the Agreement is hereby deleted in its entirety and replaced with the following: 

 “8.6 Third Party Technology. The Supervisory Board will discuss Third Party patent
rights which may be necessary for (i) Blood Screening Assays or (ii) modifications to Blood Screening Assays or Blood Screening Instruments. The Supervisory Board will consider the costs of acquiring rights in such Third Party patent
rights in connection with such Products, allocate the costs between the parties, and agree upon methods for implementing such cost allocations. Gen-Probe shall make all payments due hereunder to Novartis. Notwithstanding the foregoing, the parties
agree that Gen-Probe will not be required to share in any payment obligations of Novartis arising from the settlement or other resolution of the Current NIH–Pasteur Dispute.” 

3. The effective date of this First Amendment shall be the date on which the assignment of the Agreement from Novartis to Grifols, S.A. becomes effective. The
effectiveness of this First Amendment is contingent on and will be deemed to occur immediately prior to the Agreement being assigned to Grifols, S.A. 
 4.
Except as expressly set forth in this First Amendment, all other terms and conditions of the Agreement are hereby ratified and shall continue in full force and effect. 

5. This First Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same
instrument. 
 IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to be executed and the persons signing below warrant that they
are duly authorized to sign for and on behalf of the respective parties. 
  

							
	 NOVARTIS VACCINES AND

DIAGNOSTICS, INC.
	  	 HOLOGIC GEN-PROBE

INCORPORATED

				
	By:	  	

	  	By:	  	

	Name:	  	Kim Parker	  	Name:	  	Mark J. Casey
	Title:	  	VP, Corp. Counsel	  	Title:	  	SVP, CAO & General Counsel
	Date:	  	Nov. 8 2013	  	Date:	  	11/8/13

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}]]